GRI Bio Announces Pricing of $5.5 Million Public Offering
LA JOLLA, CA, Feb. 02, 2024 (GLOBE NEWSWIRE) — GRI Bio, Inc. (NASDAQ:GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (“NKT”) cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today announced the pricing of its “reasonable best efforts” public offering (the “Offering”) with participation from healthcare focused institutional investors for the purchase and sale of 5,000,000 shares of common stock (or common stock equivalents in lieu thereof) at a purchase price of $1.10 per share. The Company further agreed to issue to the investors Series B-1 Warrants to purchase up to 5,000,000 shares of common stock and Series B-2 Warrants to purchase up to 5,000,000 shares of common stock. The Series B-1 and Series B-2 Warrants will have an exercise price of $1.10 per share, will be exercisable immediately following the date of issuance and will expire in five years and eighteen months, respectively.
Related news for (GRI)
- From Tokens to Tailgates: VENU, DeFi Dev, and Avalanche Players Rewrite the Market’s Opening Act
- AgriFORCE Growing Systems (AGRI) to Launch as First Publicly-Traded Avalanche-Focused Company on NASDAQ with a $550 Million Capital Raise Strategy
- MoBot’s Stock Market Highlights – 09/22/25 07:00 AM
- 24/7 Market News Snapshot 22 September, 2025 – AgriFORCE Growing Systems Ltd. Common Shares (NASDAQ:AGRI)
- MoBot’s Stock Market Highlights – 09/22/25 06:00 AM